Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study - Sorbonne Université Accéder directement au contenu
Article Dans Une Revue BMC Cancer Année : 2023

Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study

Agathe Vienne
  • Fonction : Auteur
Laetitia Collet
  • Fonction : Auteur
Thomas Chevalier
  • Fonction : Auteur
Christian Borel
  • Fonction : Auteur
Magalie Tardy
  • Fonction : Auteur
Sebastien Salas
  • Fonction : Auteur
Esma Saada-Bouzid
  • Fonction : Auteur
Jerome Fayette
  • Fonction : Auteur
Amaury Daste
  • Fonction : Auteur
  • PersonId : 1302590

Résumé

Background Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) have a poor prognosis and limited therapeutic options. Immune checkpoint inhibitors (ICIs) are effective in patients with tumor progression < 6 months following first-line, platinum-based chemotherapy (PBC), but data are missing for patients with progression ≥ 6 months after the last platinum dose. Methods Retrospective analysis (six French centers, 2008–2019) of all consecutive R/M-HNSCC patients. treated first-line with PBC and tumor progression ≥ 6 months after the last platinum dose. Primary endpoint: progression-free survival after second-line therapy (PFS2). Additional endpoints: overall survival from Day 1 of first-line (OS1) and second-line (OS2) therapy. Results R/M-HNSCC patients (n = 144) received cisplatinum (n = 67, 47%) or carboplatinum (n = 77, 53%) first-line. Response after first-line: complete response (CR; n = 16, 11%); partial response (PR; n = 77, 53%); stable disease (n = 22, 15%). Second-line therapy: PBC (n = 95, 66%); platinum-free regimen (PFR) (n = 25, 17%); ICI (n = 24, 17%). Median [95% confidence interval] PFS (months): PBC 5.0 [3.8–6.2]; PFR 4.0 [1–7.0]; ICI 2.0 [0.4–3.6] (p = 0.16). For PBC, PFR, and ICI, respectively: OS1 30, 23, and 29 months (p = 1.02); OS2 14, 10, and 16 months (p = 0.25); PR, 26%, 16%, and 21% patients; CR, 0%, 8%, and 4% patients. For subsequent lines, ICIs were administered for PBC (n = 11, 12%) and PFR (n = 2, 8%). No predictive factor for efficacy (PFS, OS) was identified. Conclusions Our retrospective study suggests similar efficacy regarding OS2 for second-line chemotherapy or ICI in R/M-HNSCC patients with progression ≥ 6 months after the last first-line platinum dose.

Domaines

Cancer
Fichier principal
Vignette du fichier
s12885-023-11133-5.pdf (790.9 Ko) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

hal-04268689 , version 1 (02-11-2023)

Licence

Identifiants

Citer

Agathe Vienne, Laetitia Collet, Thomas Chevalier, Christian Borel, Magalie Tardy, et al.. Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study. BMC Cancer, 2023, 23 (1), pp.663. ⟨10.1186/s12885-023-11133-5⟩. ⟨hal-04268689⟩
7 Consultations
5 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More